These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 498169)

  • 21. [Value of intravenous Melphalan in treatment of Kahler's disease].
    Balmes A; Dauverchain J; Mandin A; Othoniel J; Vedel A
    Mars Med; 1969; 106(6):505-8. PubMed ID: 5376451
    [No Abstract]   [Full Text] [Related]  

  • 22. High-dose intravenous melphalan in a patient with multiple myeloma and oliguric renal failure.
    Pecherstorfer M; Zimmer-Roth I; Weidinger S; Irsigler K; Halbmayer WM; Ulrich W; Fischer M; Baumgartner G
    Clin Investig; 1994 Jul; 72(7):522-5. PubMed ID: 7981581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melphalan-related leukemia in multiple myeloma.
    Wahlin A; Roos G; Rudolphi O; Holm J
    Acta Med Scand; 1982 May; 211(3):203-8. PubMed ID: 7080865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
    Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypersensitivity reactions to iv melphalan during treatment of multiple myeloma: Cancer and Leukemia Group B experience.
    Cornwell GG; Pajak TF; McIntyre OR
    Cancer Treat Rep; 1979 Mar; 63(3):399-403. PubMed ID: 427822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208).
    Kyle RA; Seligman BR; Wallace HJ; Silver RT; Glidewell O; Holland JF
    Cancer Chemother Rep; 1975; 59(3):557-62. PubMed ID: 1203882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
    Cornwell GG; Pajak TF; Kochwa S; McIntyre OR; Glowienka LP; Brunner K; Rafla S; Silver RT; Cooper MR; Henderson E; Kyle RA; Haurani FI; Cuttner J
    Cancer; 1982 Nov; 50(9):1669-75. PubMed ID: 7116299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience.
    Cornwell GG; Pajak TF; McIntyre OR; Kochwa S; Dosik H
    Cancer Treat Rep; 1982 Mar; 66(3):475-81. PubMed ID: 7060036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen.
    Woodhouse KW; Hamilton P; Lennard A; Rawlins MD
    Eur J Clin Pharmacol; 1983; 24(2):283-5. PubMed ID: 6840181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [High-dose melphalan in patients with multiple myeloma].
    Moreau P; Le Bonniec M; Harousseau JL
    Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeat administration of high dose melphalan in relapsed myeloma.
    Mansi JL; Cunningham D; Viner C; Ellis E; Meldrum M; Milan S; Gore M
    Br J Cancer; 1993 Nov; 68(5):983-7. PubMed ID: 8217614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of cimetidine with oral melphalan. A pharmacokinetic study.
    Sviland L; Robinson A; Proctor SJ; Bateman DN
    Cancer Chemother Pharmacol; 1987; 20(2):173-5. PubMed ID: 3311444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
    Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
    J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Assessment of a nitrosurea combined with cyclophosphamide and prednisone versus melphalan and prednisone in the treatment of multiple myeloma (author's transl)].
    Bezares R; Bomchil G; Saslavsky J; Pavlovsky S; Curutchet M; Quiroga Micheo E; Macchi A; Musso A; Suárez A; Pizzolato M
    Sangre (Barc); 1979; 24(3):241-51. PubMed ID: 472966
    [No Abstract]   [Full Text] [Related]  

  • 36. [Changes in peripheral blood monocyte number in patients with multiple myeloma treated with melphalan].
    Mendek-Czajkowska E; Rostkowska J; Mariańska B; Sawicki Z; Maj S
    Acta Haematol Pol; 1984; 15(3-4):119-24. PubMed ID: 6537120
    [No Abstract]   [Full Text] [Related]  

  • 37. Melphalan hydrochloride for the treatment of multiple myeloma.
    Esma F; Salvini M; Troia R; Boccadoro M; Larocca A; Pautasso C
    Expert Opin Pharmacother; 2017 Aug; 18(11):1127-1136. PubMed ID: 28658983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Intermittent melphalan-predniso(lo)ne massive-dose therapy of plasmacytoma].
    Braun HJ
    Dtsch Med Wochenschr; 1972 Jan; 97(3):84-6. PubMed ID: 5007398
    [No Abstract]   [Full Text] [Related]  

  • 39. [Myeloma with hypereosinophilia. Eosinophil reaction following melphalan].
    Ozgüven O; Sebik F; Basci A
    Presse Med; 1983 Mar; 12(11):704. PubMed ID: 6220307
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
    Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
    Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.